Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Globe Newswire•28/07/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.